S&P 500

5.735,81

-0,04%

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

0RC6

Pharma Mar (0RC6)

Pharma Mar Sa

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0RC6

1

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
04/06/2024	09h00	PR Newswire (US)	PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer	LSE:0RC6	Pharma Mar Sa
11/01/2022	15h13	PR Newswire (US)	Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants	LSE:0RC6	Pharma Mar Sa
11/01/2022	15h09	PR Newswire (US)	Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants	LSE:0RC6	Pharma Mar Sa
22/12/2021	11h17	PR Newswire (US)	PharmaMar signs a new licensing and commercialization agreement with Eczacibasi for lurbinectedin in Turkey	LSE:0RC6	Pharma Mar Sa
13/12/2021	14h39	PR Newswire (US)	PharmaMar and Jazz Pharmaceuticals announce initiation of confirmatory phase III clinical trial of Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer	LSE:0RC6	Pharma Mar Sa
11/11/2021	13h39	PR Newswire (US)	PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan	LSE:0RC6	Pharma Mar Sa
28/04/2020	12h39	PR Newswire (US)	PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitid...	LSE:0RC6	Pharma Mar Sa
28/04/2020	12h35	PR Newswire (US)	PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitid...	LSE:0RC6	Pharma Mar Sa